# CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

> **NCT06027957** · PHASE1 · COMPLETED · sponsor: **Vinmec Research Institute of Stem Cell and Gene Technology** · enrollment: 18 (actual)

## Conditions studied

- B-Cell Non Hodgkin Lymphoma
- B-Cell Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** anti-CD19 CAR T-cells

## Key facts

- **NCT ID:** NCT06027957
- **Lead sponsor:** Vinmec Research Institute of Stem Cell and Gene Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-02
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-07-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06027957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06027957, "CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06027957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*